about
F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysisPreventing adverse obstetric outcomes in women with genetic thrombophiliaThe role of PC-1 and ACE genes in diabetic nephropathy in type 1 diabetic patients: evidence for a polygenic control of kidney disease progressionIncidental splanchnic vein thrombosis: preliminary registry data.High prevalence of thrombophilic genotypes in patients with acute mesenteric vein thrombosis.A novel mutation in human ether-a-go-go-related gene, alanine to proline at position 490, found in a large family with autosomal dominant long QT syndrome.The G20210A prothrombin variant and the risk of venous thromboembolism or fetal loss in pregnant women: a family study.Inherited platelet disorders: thrombocytopenias and thrombocytopathies.Clinical utility of antithrombotic prophylaxis in ART procedures: an Italian experience.Identification of FVIII gene mutations in patients with hemophilia A using new combinatorial sequencing by hybridization.Homocysteine, platelet function and thrombosis.Atherosclerosis in thrombotic primary antiphospholipid syndrome.Assessment of the olfactory function in Italian patients with type 3 von Willebrand disease caused by a homozygous 253 Kb deletion involving VWF and TMEM16B/ANO2Inherited thrombophilia and gestational vascular complications.McKusick-Kaufman or Bardet-Biedl syndrome? A new borderline case in an Italian nonconsanguineous healthy family.Mechanisms of fibrinolysis and clinical use of thrombolytic agents.The Relationship between Personality Traits, the 5HTT Polymorphisms, and the Occurrence of Anxiety and Depressive Symptoms in Elite Athletes.Pregnancy-related venous thrombosis: comparison between spontaneous and ART conception in an Italian cohortRole of tumour necrosis factor alpha and interleukin 1 beta in promoter effect induced by mercury in human keratinocytes.TET2 mutations in Ph-negative myeloproliferative neoplasms: identification of three novel mutations and relationship with clinical and laboratory findings.Oral anticoagulants: Pharmacogenetics Relationship between genetic and non-genetic factors.Prevention and treatment of bleeding complications in patients receiving vitamin K antagonists, Part 1: Prevention.Role of thrombophilia in adverse obstetric outcomes and their prevention using antithrombotic therapy.Genetic basis of thrombosis.Searching for the thrombogenic mechanism(s) of fibrinogen.Low-dose aspirin for in vitro fertilization or intracytoplasmic sperm injection: a systematic review and a meta-analysis of the literature.Modulation of factors involved in placental haemostasis and angiogenesis by low-molecular-weight-heparins.A G-to-A mutation in IVS-3 of the human gamma fibrinogen gene causing afibrinogenemia due to abnormal RNA splicing.Hemostatic variables and ischemic cardiovascular disease: do we need a concerted effort for more profitable future clinical investigations?Role of CYP2D6 Polymorphisms in the Outcome of Postoperative Pain Treatment.Drugs affecting plasma fibrinogen levels. Implications for new antithrombotic strategies.Characterization of patients with angioedema without wheals: the importance of F12 gene screening.Variation in genes encoding for interferon λ-3 and λ-4 in the prediction of HCV-1 treatment-induced viral clearance.Perceived challenges and attitudes to regimen and product selection from Italian haemophilia treaters: the 2013 AICE survey.Identification of naïve HCV-1 patients with chronic hepatitis who may benefit from dual therapy with peg-interferon and ribavirin.EPCR Ser219Gly: elevated sEPCR, prothrombin F1+2, risk for coronary heart disease, and increased sEPCR shedding in vitro.Effects of ethylene oxide and steam sterilization on dialysis-induced cytokine release by cuprophan membrane.Gain-of-function gene mutations and venous thromboembolism: distinct roles in different clinical settingsReply to "triple or dual therapy for HCV-1 naive patients? Optimizing selection tools".Polymorphisms in genes involved in autoimmune disease and the risk of FVIII inhibitor development in Italian patients with haemophilia A.
P50
Q26827191-DF533427-1086-4AED-866E-43214EC23A99Q28193486-DC9976A8-B561-4E96-B673-61EB7ADAC28BQ28216371-2D9AF35C-404F-4ADF-B0D5-1FC40F307315Q31105709-1DEC801D-74D4-4040-9414-5076292FDEF3Q31987604-A98A4937-19A3-48DF-9F38-543395C71EC2Q33155214-EBD4CF6E-DD44-40E9-A21D-9B676D4D6CC7Q33303765-E67AAF42-C633-4290-9669-57C4E6490465Q33387543-28D7158E-CC61-4457-8530-308F10D8E0B4Q33679476-5D6ED970-DE83-4397-BC96-EECF06EA00DEQ33735836-42745D82-7920-4D41-911C-C8078A99E87DQ33976995-45B12C32-A67A-4135-90B1-DBB2D782399AQ34015917-721ADCAF-A6DE-4111-A26B-22498E4AD2B1Q35032193-AF128F47-EF9C-47D5-9CD9-38345D257EF0Q35134533-51D3E754-25A4-495A-863C-F4A6BD7DD15DQ35544722-2F11C7F3-6A92-4F51-8A64-75B4F9FB932BQ35644040-1B2B91AE-F16D-4AFB-A238-D03B257C7D3CQ36039447-B382FD1E-6841-4AB0-AF6D-1F39E7C5E8AEQ36178815-0760BE5F-52A0-4E64-B5C9-86C4ED44D8D6Q36732742-126726EA-4D2A-4B49-8318-27FC14BFB28BQ36916115-C1A9E6F2-24F1-472D-B383-DA0599B0580DQ37072091-754BBD5B-0782-478B-92E8-83B778A49979Q37554153-3DDEC9B6-3B19-4655-B867-724AFEF449AEQ37655829-0A31B8F4-FCCB-496B-805A-07861EE50256Q37804873-D188A614-171D-4255-8CDD-24626422C86AQ38025170-4622A2F9-127A-4619-B157-861B1125D1F3Q38035348-8EF04A61-CBD0-434C-AD20-A77F6A7F8897Q39448592-41D7E908-9026-48E7-BAD8-E313023102CBQ40852987-DA139D80-17D7-4332-9305-478E979C2646Q40913617-89A1F443-4713-4FE6-A768-F27C015AA9A1Q40924040-8D756703-9586-48BE-9DDE-6CC365EE6849Q41074167-489D3FC8-252A-4F3B-8EE0-E3895A649347Q41285230-2A5D2068-9873-42E3-A0A7-5D926E2319C4Q41715697-4D1EA040-CB8B-43B0-BC5B-B5617EF6E1C5Q42236600-7CB21F2D-5984-46D7-8351-6CE8F31B8485Q42249962-93AE8ECB-15B7-4399-9ACA-7CA29783C7F3Q42478892-4F29256B-3A36-4D1B-98CD-3E77FA7472B6Q42522561-A5157152-3CEE-4DEF-A73C-8D4FB9A7C7D4Q42550935-FF114A21-4C10-4E05-A06D-19EE1EBA0055Q43001488-B1DD3246-6C31-46E4-9306-F6805710A2AEQ43218663-E55A6ACD-143D-4C0D-9766-2BB3FD093F00
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Maurizio Margaglione
@ast
Maurizio Margaglione
@en
Maurizio Margaglione
@es
Maurizio Margaglione
@nl
Maurizio Margaglione
@sl
type
label
Maurizio Margaglione
@ast
Maurizio Margaglione
@en
Maurizio Margaglione
@es
Maurizio Margaglione
@nl
Maurizio Margaglione
@sl
prefLabel
Maurizio Margaglione
@ast
Maurizio Margaglione
@en
Maurizio Margaglione
@es
Maurizio Margaglione
@nl
Maurizio Margaglione
@sl
P106
P21
P31
P496
0000-0001-5627-9221